[go: up one dir, main page]

IL126547A - Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf) - Google Patents

Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf)

Info

Publication number
IL126547A
IL126547A IL12654797A IL12654797A IL126547A IL 126547 A IL126547 A IL 126547A IL 12654797 A IL12654797 A IL 12654797A IL 12654797 A IL12654797 A IL 12654797A IL 126547 A IL126547 A IL 126547A
Authority
IL
Israel
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
production
Prior art date
Application number
IL12654797A
Other languages
English (en)
Other versions
IL126547A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to IL15208397A priority Critical patent/IL152083A0/xx
Publication of IL126547A0 publication Critical patent/IL126547A0/xx
Publication of IL126547A publication Critical patent/IL126547A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL12654797A 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf) IL126547A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL15208397A IL152083A0 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (2)

Publication Number Publication Date
IL126547A0 IL126547A0 (en) 1999-08-17
IL126547A true IL126547A (en) 2003-03-12

Family

ID=21779401

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12654797A IL126547A (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf)
IL15208397A IL152083A0 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf)

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15208397A IL152083A0 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf)

Country Status (41)

Country Link
US (2) US6211222B1 (xx)
EP (1) EP0912521B1 (xx)
JP (1) JP3148254B2 (xx)
KR (1) KR100339935B1 (xx)
CN (2) CN1112359C (xx)
AP (4) AP2001002304A0 (xx)
AR (1) AR006906A1 (xx)
AT (1) ATE292626T1 (xx)
AU (1) AU725576B2 (xx)
BG (1) BG64211B1 (xx)
BR (1) BR9709051A (xx)
CA (2) CA2389918A1 (xx)
CO (1) CO4650038A1 (xx)
CZ (1) CZ292825B6 (xx)
DE (1) DE69732966T2 (xx)
DZ (1) DZ2217A1 (xx)
EA (1) EA002272B1 (xx)
ES (1) ES2238079T3 (xx)
GT (1) GT199700043A (xx)
HN (1) HN1997000046A (xx)
HR (1) HRP970227B1 (xx)
HU (1) HUP9902459A3 (xx)
ID (1) ID16856A (xx)
IL (2) IL126547A (xx)
IS (1) IS4871A (xx)
MA (1) MA24158A1 (xx)
MY (1) MY132499A (xx)
NO (1) NO312959B1 (xx)
NZ (1) NZ332240A (xx)
OA (1) OA10904A (xx)
PE (1) PE64598A1 (xx)
PL (1) PL329836A1 (xx)
SK (1) SK148298A3 (xx)
TN (1) TNSN97070A1 (xx)
TR (1) TR199802202T2 (xx)
TW (1) TW449585B (xx)
UA (1) UA65536C2 (xx)
UY (1) UY24532A1 (xx)
WO (1) WO1997042174A1 (xx)
YU (1) YU16397A (xx)
ZA (1) ZA973804B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
PT983249E (pt) 1997-05-08 2002-08-30 Pfizer Prod Inc Procesos e intermediarios para a preparacao de derivados de indazole substituidos
EA200000385A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
EA200000488A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Замена катехина на биоизостеру индазола в терапевтически активных соединениях
IL126745A (en) 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
IL132407A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6303782B1 (en) * 1999-04-20 2001-10-16 Pfizer Inc Process for preparing benzylnitriles
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
WO2003051344A1 (en) 2001-12-14 2003-06-26 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation_using a non-polypeptide camp level modulator
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8277809B2 (en) * 2006-04-21 2012-10-02 Centocor, Inc. CXCL13 antagonists and their use for the treatment of inflammatory diseases
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (xx) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
EP0630367B1 (en) * 1992-03-09 2000-07-05 Zeneca Limited Novel arylindazoles and their use as herbicides
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
EP0787132A1 (en) * 1994-10-20 1997-08-06 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
JPH10509469A (ja) * 1994-10-21 1998-09-14 エリシャ・テクノロジーズ・カンパニー・エルエルシー 金属製造物のための腐食抵抗緩衝系
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
PT983249E (pt) * 1997-05-08 2002-08-30 Pfizer Prod Inc Procesos e intermediarios para a preparacao de derivados de indazole substituidos

Also Published As

Publication number Publication date
UA65536C2 (en) 2004-04-15
IL152083A0 (en) 2003-05-29
YU16397A (sh) 1999-12-27
MA24158A1 (fr) 1997-12-31
HRP970227A2 (en) 2000-12-31
OA10904A (en) 2001-10-11
CZ292825B6 (cs) 2003-12-17
JPH11508284A (ja) 1999-07-21
AP2001002304A0 (en) 2001-12-31
DE69732966T2 (de) 2005-09-08
HN1997000046A (es) 1997-06-26
AP1147A (en) 2003-02-25
NZ332240A (en) 2000-07-28
EP0912521A1 (en) 1999-05-06
CN1112359C (zh) 2003-06-25
CN1217714A (zh) 1999-05-26
AP1146A (en) 2003-02-25
CA2252982C (en) 2002-10-08
CA2389918A1 (en) 1997-11-13
UY24532A1 (es) 2000-09-29
AU1937397A (en) 1997-11-26
SK148298A3 (en) 2000-02-14
TR199802202T2 (xx) 1999-02-22
DZ2217A1 (fr) 2002-12-03
PL329836A1 (en) 1999-04-12
AP2001002294A0 (en) 2001-12-31
ES2238079T3 (es) 2005-08-16
CO4650038A1 (es) 1998-09-03
EA002272B1 (ru) 2002-02-28
AU725576B2 (en) 2000-10-12
US6127398A (en) 2000-10-03
AP9700975A0 (en) 1997-07-31
JP3148254B2 (ja) 2001-03-19
HRP970227B1 (en) 2002-06-30
HUP9902459A3 (en) 2001-10-29
BG64211B1 (bg) 2004-05-31
ZA973804B (en) 1998-11-02
CA2252982A1 (en) 1997-11-13
NO312959B1 (no) 2002-07-22
TNSN97070A1 (fr) 2005-03-15
KR100339935B1 (ko) 2002-07-18
ID16856A (id) 1997-11-13
CZ349298A3 (cs) 1999-09-15
EA199800882A1 (ru) 1999-06-24
CN1422849A (zh) 2003-06-11
AR006906A1 (es) 1999-09-29
US6211222B1 (en) 2001-04-03
HUP9902459A2 (hu) 1999-11-29
EP0912521B1 (en) 2005-04-06
DE69732966D1 (de) 2005-05-12
KR20000010751A (ko) 2000-02-25
WO1997042174A1 (en) 1997-11-13
IL126547A0 (en) 1999-08-17
PE64598A1 (es) 1998-10-26
ATE292626T1 (de) 2005-04-15
HK1019443A1 (en) 2000-02-11
GT199700043A (es) 1998-10-02
BR9709051A (pt) 1999-08-03
TW449585B (en) 2001-08-11
NO985095L (no) 1998-12-29
BG102946A (en) 1999-11-30
AP0102304A0 (en) 1997-11-03
MY132499A (en) 2007-10-31
NO985095D0 (no) 1998-11-02
IS4871A (is) 1998-10-16

Similar Documents

Publication Publication Date Title
IL128642A0 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
HUP9902459A3 (en) Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
HUP9903009A3 (en) Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
AU3102697A (en) Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
AU3588693A (en) N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
HUP0004512A3 (en) 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
NZ292991A (en) Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
AU4960297A (en) Bicyclic aryl carboxamides and their therapeutic use
AU3885900A (en) Inhibitors of the egf-receptor tyrosine kinase and their use
HUP9902026A3 (en) Use of bicyclic 4-aralkylaminopyrimidine derivatives for producing pharmaceutical compositions having tyrosine kinase inhibitor effect, novel bicicyclic 4-aralkylaminopirimidine derivatives and pharmaceutical compositions containing them
PL329855A1 (en) Inhibitors of s-cd23 formation and tumour necrosis factor release
AU642772B2 (en) Inhibitors for the formation of tumor necrosis factor, processes for the preparation thereof and the use thereof
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
PT934307E (pt) Compostos azabicíclicos substituídos e sua utilização como inibidores da produção de tnf e da fosfodiesterase do amp cíclico
HK1026898A (en) Quinoline derivatives as pde iv and/or tnf inhibitors
HK1012391A (en) Imidazole derivatives and their use as cytokine inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees